Table. Percentage of Patients With Adverse Events According to Treatment.
| Treatment | Grades, No./Total No. (%)a | Source, Reference No. | |
|---|---|---|---|
| 3-4 | All | ||
| Dactolisib | 26/31 (83.9) | 31/31 (100) | 28 |
| Everolimus + somatostatin analogue | 67/98 (68.4) | 81/98 (82.7) | 27, 41 |
| Capecitabine + streptozocin + cisplatin | 25/40 (62.5) | 37/40 (92.5) | 42 |
| Everolimus | 309/521 (59.3) | 291/316 (92.1) | 1, 27, 29, 31, 32, 40 |
| Capecitabine + streptozocin | 18/43 (41.9) | 41/43 (95.3) | 42 |
| 177Lu-dotatate + somatostatin analogue | 46/111 (41.4) | 105/111 (94.6) | 37 |
| Hepatic arterial chemoembolization | 3/12 (25.0) | 11/12 (91.7) | 49 |
| Somatostatin analogue | 72/344 (20.9) | 226/324 (69.8) | 26, 37, 39, 41, 45, 50 |
| Placebo | 92/480 (19.2) | 278/363 (76.6) | 26, 29, 32, 45, 46, 50 |
| Hepatic arterial embolization | 2/14 (14.3) | 12/14 (85.7) | 49 |
| Interferon + somatostatin analogue | 1/33 (3.0) | 7/33 (21.2) | 39 |
| Telotristat | 0 | 79/90 (87.8) | 46 |
Abbreviation: 177Lu-dotatate, radiolabeled lutetium Lu 177–dotatate.
a
Adverse events were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events: grade 1, mild; grade 2, moderate; grade 3, severe or medically significant; and grade 4, life-threatening.